New hope for kids with deadly brain cancer? drug ONC206 enters human trials
NCT ID NCT04732065
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called ONC206 in children and young adults with diffuse midline glioma or other recurrent brain tumors. The drug aims to kill cancer cells by causing stress in them, without harming healthy cells. Researchers are looking for the safest dose and checking for side effects, with up to 208 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONC206
What this could lead to
If successful, this could point toward a new treatment option for children with aggressive brain tumors like diffuse midline glioma.
What could go wrong
This is an early phase 1 trial, so the drug may not work or could have side effects. It is small and focused on safety, not yet proving effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
-
Princess Máxima Center for Pediatric Oncology
RECRUITINGUtrecht, 3584, Netherlands
Contact Phone: •••-•••-••••
Contact Email: •••••@•••••
Contact
-
The University Children's Hospital in Zurich
RECRUITINGZurich, Canton of Zurich, 8032, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Email: •••••@•••••